XM tillhandahåller inte tjänster till personer bosatta i USA.
I
I

IQVIA


Nyheter

India's Aurobindo Pharma up on FDA nod for product treating menopause condition

BUZZ-India's Aurobindo Pharma up on FDA nod for product treating menopause condition ** Shares of Aurobindo Pharma ARBN.NS rise as much as 2.7% to 1,439.90 rupees, among top gainers in Nifty Pharma index .NIPHARM ** Co on Tuesday received U.S. FDA nod to make and market estradiol vaginal suppositories - a bioequivalent to Novo Nordisk's VAGIFEM - used treat a condition resulting from menopause ** Product has estimated market size of $268 million for the 12 months ended June 2024, as per pharma c
I

Medpace tumbles after bookings disappoint

BUZZ-Medpace tumbles after bookings disappoint ** Medpace's MEDP.O shares down 13.6% premarket to three-mth low $377.91 after clinical contract research organization's bookings miss expectations ** Co late Mon reported Q2 new business awards decreased 4% yr/yr for net book-to-bill ratio (number of orders received to those fulfilled) of 1.04x ** TD Cowen, which rates MEDP "buy", pointed out that consensus called for book-to-bill ratio of 1.23x ** While unclear what drove bookings weakness, some e
I

U.S. Colgate-Palmolive, McKesson, Microsoft

U.S. RESEARCH ROUNDUP-Colgate-Palmolive, McKesson, Microsoft July 23 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Colgate-Palmolive, McKesson and Microsoft, on Tuesday. HIGHLIGHTS * Colgate-Palmolive Co CL.N : TD Cowen initiates coverage with buy rating; PT $110 * DR Horton Inc DHI.N : JP Morgan raises target price to $180 from $163 * IQVIA Holdings Inc IQV.N : Baird raises target price to $251 from $235 * McKesso
C
H
M
M
T
V
Z
F
A
M
A
C
C
D
I

S&P 500 top and bottom performing stocks at about 03:30 p.m. EDT

BUZZ - S&P 500 top and bottom performing stocks at about 03:30 p.m. EDT S&P 500 .SPX Top Performers Percent Change IQVIA Holdings Inc IQV.N +7.7% Lam Research Corp LRCX.OQ +6% ON Semiconductor Corp ON.OQ +5.9% Applied Materials Inc AMAT.OQ +5.8% KLA Corp KLAC.OQ +5.5% Bottom Performers Percent Change CrowdStrike Holdings Inc CRWD.OQ -13.2% Verizon
S
V
K
L
O
U
A
C
I

U.S. STOCKS Walt Disney, Mattel, Tellurian

BUZZ-U.S. STOCKS ON THE MOVE-Walt Disney, Mattel, Tellurian Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The S&P 500 and the Nasdaq recouped some of the previous week's losses on Monday, as investors reexamined the chances of a second presidential term for Republican nominee Donald Trump after U.S.
G
M
N
S
S
V
A
C
L
U
U
A
G
I
N

S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT

BUZZ - S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT S&P 500 .SPX Top Performers Percent Change IQVIA Holdings Inc IQV.N +6.6% ON Semiconductor Corp ON.OQ +4.7% Lam Research Corp LRCX.OQ +4.2% Applied Materials Inc AMAT.OQ +3.9% KLA Corp KLAC.OQ +3.9% Bottom Performers Percent Change CrowdStrike Holdings Inc CRWD.OQ -13.0% Verizo
S
V
K
L
O
U
A
C
I

U.S. STOCKS Verizon Communications, Reddit, Starbucks

BUZZ-U.S. STOCKS ON THE MOVE-Verizon Communications, Reddit, Starbucks Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street rose on Monday, regaining some ground after the previous week's declines as investors assessed the odds of a second term for Republican nominee Donald Trump in the November election after President Joe Biden withdrew from the race.
G
N
S
S
V
A
C
L
O
U
U
G
I

IQVIA climbs on annual profit forecast raise

BUZZ-IQVIA climbs on annual profit forecast raise ** Shares of contract research firm IQVIA Holdings IQV.N rise ~6.7% to $239.60, highest since April ** Co forecasts annual adj. profit between $11.10 and $11.30 per share, above its prior range of $10.95 to $11.25 ** Co reports Q2 adj. profit of $2.64/shr vs analysts' average estimate of $2.57/shr -
I

IQVIA Holdings Inc reports results for the quarter ended in January - Earnings Summary

IQVIA Holdings Inc reports results for the quarter ended in January - Earnings Summary IQVIA Holdings Inc IQV.N reported quarterly adjusted earnings of $2.64​​ per share for the quarter ended in January, higher than the same quarter last year, when the company reported EPS of $2.43. The mean expectation of twenty one analysts for the quarter was for earnings of $2.57 per share.
I

IQVIA raises annual profit forecast on improving demand for analytics services

IQVIA raises annual profit forecast on improving demand for analytics services July 22 (Reuters) - Contract research firm IQVIA Holdings IQV.N raised its forecast for full-year profit on Monday, banking on strength in demand for its healthcare data and analytics services. Technological and analytical solutions (TAS), IQVIA's second-largest unit, reported a 2.7% rise in second-quarter revenue to $1.50 billion, above estimates of $1.47 billion, according to LSEG data.
I

IQVIA Q2 Adjusted EPS USD 2.64 Vs. IBES Estimate USD 2.57

BRIEF-IQVIA Q2 Adjusted EPS USD 2.64 Vs. IBES Estimate USD 2.57 Jul 22 (Reuters) - IQVIA Q2 net income USD 363 million. Q2 revenue USD 3,814 million vs. IBES estimate USD 3,789 million Q2 adjusted EBITDA USD 887 million vs. IBES estimate USD 884 million Q2 EPS USD 1.97
I

Biden bows out, election bets shift, China cuts

MORNING BID AMERICAS-Biden bows out, election bets shift, China cuts A look at the day ahead in U.S. and global markets from Mike Dolan U.S. President Joe Biden's weekend withdrawal from the White House race can hardly be seen as a big surprise, but it adds some doubts to market bets that Republican challenger Donald Trump is a shoo-in in November's election.
B
C
D
G
G
L
N
N
T
U
U
V
G
J
U
U
U
F
W
I

IQVIA Holdings Inc <IQV.N> expected to post earnings of $2.57 a share - Earnings Preview

IQVIA Holdings Inc expected to post earnings of $2.57 a share - Earnings Preview IQVIA Holdings Inc IQV.N , IQV is expected to show a rise in quarterly revenue when it reports results on July 22 for the period ending June 30 2024 The Durham North Carolina-based company is expected to report a 1.6% increase in revenue to $3.789 billion from $3.73 billion a year ago, according to the mean estimate from 18 analysts, based on LSEG data.The company's guidance on May 2 2024, for the period ended June
I

Novo Nordisk obesity feast no longer a free lunch

BREAKINGVIEWS-Novo Nordisk obesity feast no longer a free lunch The author is a Reuters Breakingviews columnist. The opinions expressed are her own. By Aimee Donnellan LONDON, July 18 (Reuters Breakingviews) - Novo Nordisk NOVOb.CO is going to have to work hard to justify its bulging valuation. The $603 billion obesity drug maker’s shares have more than trebled since 2021 thanks to insatiable appetite for its weight-loss drug.
A
P
R
I

U.S. Avidity Biosciences, Broadcom, Cara Therapeutics

U.S. RESEARCH ROUNDUP-Avidity Biosciences, Broadcom, Cara Therapeutics June 13 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Avidity Biosciences, Broadcom and Cara Therapeutics, on Thursday. HIGHLIGHTS * Avidity Biosciences Inc RNA.O : Leerink Partners raises target price to $56 from $38 * Broadcom Inc AVGO.O : TD Cowen raises target price to $1,750 from $1,500 * Cara Therapeutics Inc CARA.O : Canaccord Genuity cut
B
B
C
C
G
M
C
A
D
I
L

Iqvia Launches “One Home” Clinical Trial Technology Platform – Solves Challenges And Reduces Overload At Sites

BRIEF-Iqvia Launches “One Home” Clinical Trial Technology Platform – Solves Challenges And Reduces Overload At Sites June 12 (Reuters) - IQVIA Holdings Inc IQV.N : IQVIA LAUNCHES “ONE HOME” CLINICAL TRIAL TECHNOLOGY PLATFORM – SOLVES CHALLENGES AND REDUCES OVERLOAD AT SITES Source text for Eikon: ID:nBw7w4l7Ta Further company coverage:
I

UK's Hikma gains as Citi raises target price

BUZZ-UK's Hikma gains as Citi raises target price ** Shares of British drugmaker Hikma Pharmaceuticals HIK.L up 3% at 1,989p ** Stock is top pct gainer on FTSE 100 index .FTSE ** Brokerage Citigroup raises target price to 2845p from 2770p ** Research firm IQVIA's data on HIK highly encouraging; we go to the top-end of forecast range - Citi ** Hikma
H
U
I



Villkor

Populära tillgångar

Ansvarsfriskrivning: XM Group-enheter tillhandahåller sin tjänst enbart för exekvering och tillgången till vår onlinehandelsplattform, som innebär att en person kan se och/eller använda tillgängligt innehåll på eller via webbplatsen, påverkar eller utökar inte detta, vilket inte heller varit avsikten. Denna tillgång och användning omfattas alltid av i) villkor, ii) riskvarningar och iii) fullständig ansvarsfriskrivning. Detta innehåll tillhandahålls därför uteslutande som allmän information. Var framför allt medveten om att innehållet på vår onlinehandelsplattform varken utgör en uppmaning eller ett erbjudande om att ingå några transaktioner på de finansiella marknaderna. Handel på alla finansiella marknader involverar en betydande risk för ditt kapital.

Allt material som publiceras på denna sida är enbart avsett för utbildnings- eller informationssyften och innehåller inte – och ska inte heller anses innehålla – rådgivning och rekommendationer om finansiella frågor, investeringsskatt eller handel, dokumentation av våra handelskurser eller ett erbjudande om, eller en uppmaning till, en transaktion i finansiella instrument eller oönskade finansiella erbjudanden som är riktade till dig.

Tredjepartsinnehåll, liksom innehåll framtaget av XM såsom synpunkter, nyheter, forskningsrön, analyser, kurser, andra uppgifter eller länkar till tredjepartssajter som återfinns på denna webbplats, tillhandahålls i befintligt skick, som allmän marknadskommentar, och utgör ingen investeringsrådgivning. I den mån som något innehåll tolkas som investeringsforskning måste det noteras och accepteras att innehållet varken har varit avsett som oberoende investeringsforskning eller har utarbetats i enlighet med de rättsliga kraven för att främja ett sådant syfte, och därför är att betrakta som marknadskommunikation enligt tillämpliga lagar och föreskrifter. Se till så att du har läst och förstått vårt meddelande om icke-oberoende investeringsforskning och riskvarning om ovannämnda information, som finns här.

Riskvarning: Ditt kapital riskeras. Hävstångsprodukter passar kanske inte alla. Se vår riskinformation.